ArticleBMC surgery2022
Effectiveness of Hemopatch® versus Surgicel® Original to control mild and moderate liver bleeding.
Article in BMC surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07788846 (A Prospective, Randomized, Controlled, Assessor-Blinded, Three-Arm Clinical Trial Comparing Fibrillar Type-I Collagen Haemostat, Bone Wax, and Standardized Compression for Control of Cancellous Bone Marrow Bleeding Following Single-Ray Amputation), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Randomized, Controlled, Assessor-Blinded, Three-Arm Clinical Trial Comparing Fibrillar Type-I Collagen Haemostat, Bone Wax, and Standardized Compression for Control of Cancellous Bone Marrow Bleeding Following Single-Ray Amputation
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
- Safety and efficacy of HLBLS-200 (BleeFix) as a novel hemostatic agent in hepatic surgery: a multicenter, randomized, active-controlled clinical trial.Annals of surgical treatment and research · 2026Article
- Recent Trends in the Application of Cellulose-Based Hemostatic and Wound Healing Dressings.Journal of functional biomaterials · 2025Review
- Animal models of hemorrhage, parameters, and development of hemostatic methods.Laboratory animal research · 2025Review
- A comparative analysis of collagen based dressings and polysaccharide microspheres for hemostasis management in hepatic stab wounds.Scientific reports · 2025Article
- Chitosan-Based Biomaterials for Hemostatic Applications: A Review of Recent Advances.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjunct hemostats can be of use in certain surgical settings. We compared the effectiveness of two hemostats, Hemopatch® and Surgicel® Original in controlling bleeding from liver lesions in an experimental model.
methodsControl of grades 1 (mild) and 2 (moderate) bleeding (according to the Validated Intraoperative Bleeding [VIBe] SCALE) was assessed for 10 min after Hemopatch® (n = 198) or Surgicel® Original (n = 199) application on 397 liver surface lesions. The primary endpoint was hemostatic success (reaching VIBe SCALE grade 0 at 10 min). The secondary endpoint was time to hemostasis (time to reach and maintain grade 0). A generalized linear mixed model and an accelerated failure time model were used to assess the primary and secondary endpoints, respectively.
resultsThe overall hemostatic success rate of Hemopatch® was statistically significantly superior to that of Surgicel® Original (83.8% versus 73.4%; p = 0.0036; odds ratio [OR] 2.38, 95% confidence interval [CI] 1.33-4.27) and time to hemostasis was reduced by 15.9% (p = 0.0032; 95% CI 0.749-0.944). Grade 2 bleeds treated with Hemopatch® had statistically significantly higher hemostatic success (71.7% versus 48.5%; p = 0.0007; OR 2.97, 95% CI 1.58-5.58) and shorter time to hemostasis (49.6% reduction, p = 3.6 × 10
conclusionsHemopatch® provided better control of VIBe SCALE bleeding compared to Surgicel® Original for Grade 2 bleeds in this porcine model, highlighting the importance of choosing a suitable hemostat to optimize control of bleeding during surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.